ClinicalTrials.gg
CompletedNCT03084237Updated May 17, 2024Results posted

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

A Phase 3 interventional study of HLX02 and Herceptin® in Breast Cancer, sponsored by Shanghai Henlius Biotech. Completed at 88 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2016, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
652
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Breast Neoplasms by Fosun Pharma — 9 open to participants now, 10 under way, 4 of them phase 3. Breast Neoplasms · Fosun Pharma.

Enrollment
4th of 13
652 · median 180
Started
2016
the only one that year
Phase 3
3 of 13
1 open now
Registered
1st of 13
by date

Among the 13 studies in Breast Neoplasms by Fosun Pharma, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 1st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 13 studies in Breast Neoplasms by Fosun Pharma are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Breast Neoplasms by Fosun Pharma, or all of them as a file.
02

Study summary

This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.

Read the detailed description

This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, recurrent or previously untreated metastatic breast cancer. Eligible patients will be assessed centrally for HER2 status and the presence of at least one measurable target lesion before randomization. Patients will undergo a tumor assessment for evaluation of response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) every 6 weeks up to 24 weeks (regardless of the number of cycles actually given); thereafter, assessments will be done every 9 weeks (after Cycles 11, 14, and 17) or earlier in the case of clinical signs of progression.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have voluntarily agreed to participate and given written .
  • Male or female ≥18 years of age on day of signing the informed consent form (ICF).
  • or cytologically confirmed adenocarcinoma of the breast.
  • Recurrent disease not amenable to curative surgery or radiation therapy, or disease with an indication for a taxane-containing therapy.
  • Availability of formalin-fixed paraffin-embedded (FFPE) tissue block from the primary tumor, or a metastatic lesion, to confirm -positivity by the central laboratory, based on FISH amplification ratio ≥2.0 or IHC score 3+, and for hormone status (ER/PgR) determination (local or central laboratory). If not possible, a fresh is required.
  • No prior systemic anticancer agent such as chemotherapy, biological or targeted agent for metastatic disease with the exception of hormonal therapy, which must be stopped at least 2 weeks before randomization. Use of herbal remedies or traditional Chinese medicines for anticancer, hematologic or liver function, or anti-infective treatment must be stopped at the time of the ICF signature (at least 2 weeks before randomization).
  • For patients with recurrent disease, prior neo-/ therapy containing trastuzumab and/or lapatinib must have been stopped at least 12 months before the diagnosis of recurrent (local or metastatic) disease. If trastuzumab/lapatinib was not used, prior neo-/adjuvant therapy with a taxane must have been stopped at least 6 months before the diagnosis of recurrent (local or metastatic) disease. If only other cytotoxics were given, they must be stopped at least 4 weeks before randomization. Any hormonal therapy must be stopped at the time of the ICF signature.
  • (at least one measurable target lesion assessed by CIR; bone-only or central nervous system [CNS]-only metastases are not allowed).
  • (ECOG) performance status of 0-1.
  • within institutional range of normal at baseline (within 42 days before randomization) as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scan.
  • Adequate hematologic, hepatic and renal function as indicated by the following laboratory values:
  • (ANC) ≥1,500/μL without granulocyte-colony stimulating factor (G-CSF) or other medical support
  • ≥100,000/μL
  • ≥9 g/dL without transfusion or other medical support within 14 days
  • Serum creatinine ≤1.5 x (ULN) and rate ≥50 mL/min, calculated according to Cockroft-Gault formula
  • Serum total ≤1.5 x ULN (unless the patient has documented ·Gilbert's syndrome) without any medical support within 14 days
  • Serum /glutamicoxaloacetic transaminase (AST/SGOT) or serum alanine aminotransferase/glutamate-pyruvate transaminase (ALT/SGPT) ≤2.5 x ULN (≤5 x ULN in the case of liver metastases) provided alkaline phosphatase (ALK) is ≤2.5 x ULN. In the case of bone metastasis, serum ALK can be >2.5 x ULN if AST and ALT are ≤1.5 x ULN without any medical support within 14 days
  • (INR), and activated partial prothrombin time (aPTT) or partial prothrombin time (PTT) ≤1.5 x ULN.
  • Estimated ≥3 months.
  • Female patients are eligible to enter and participate in the study if they are of: Non-. Childbearing potential, have a negative serum pregnancy test at Screening, are not breast feeding, and use highly-effective or acceptable measures before study entry and throughout the study until 7 months after the last /comparator product administration. Highly-effective or acceptable contraceptive measures.
  • Male patients with partners of childbearing potential are eligible to enter and participate in the study if they, and their female partners, are willing to use highly-effective or acceptable contraceptive measures before study entry and throughout the study until 7 months after the last investigational/comparator product administration.

Exclusion criteria

Exclusion Criteria

  • Previously- or currently-treated (systemic chemotherapy, biological, or targeted agent, or any other anticancer agent) breast cancer with the exception of hormonal therapy.
  • Known or other CNS metastasis that is either symptomatic or untreated. Central nervous system metastases that have been treated by complete resection and/or radiotherapy demonstrating stability or improvement are not an exclusion criterion provided they are stable as shown by computed tomography (CT) scan for at least 4 weeks before Screening without evidence of cerebral edema and no requirements for or anticonvulsants.
  • Participation in another clinical study within 4 weeks before enrollment (3 months for studies involving monoclonal therapy) or the intention of participating in another clinical study during any part of the study period.
  • History of other within the last 5 years, except for carcinoma in-situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.
  • Known history of (HIV). active infection requiring therapy; positive tests for ; or .
  • Underlying medical conditions or current severe, uncontrolled systemic disease that, in the Investigator's opinion, will make the administration of study drug hazardous. A major surgical procedure within 4 weeks prior to enrollment or anticipation of the need for major surgery during the course of study.
  • Current uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg) or unstable angina.
  • History of chronic heart failure based on any (NYHA) criteria, or left ventricular hypertrophy. Current serious cardiac arrhythmia requiring treatment or clinically significant conduction defects as seen on (ECG). History of myocardial infarction within 6 months of randomization. History of decline to below 50% during or after previous trastuzumab or adjuvant therapy. Significant cardiac murmurs either on examination or ECHO.
  • History of prior exposure to doxorubicin >360 mg/m² (or equivalent). Use of oral, injected or implanted hormonal methods of . Chronic daily use of corticoids (equivalent to >10 mg/day methylprednisolone) by oral intake (inhalation is permitted).
  • Known to any of the study drugs.
  • Residual non-hematologic toxicity ≥ Grade 2 from prior therapy.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
652 participants (actual)

Study arms

  • Experimental
    HLX02+Docetaxel

    HLX02+Docetaxel

    Biological: HLX02 · Drug: docetaxel

  • Active comparator
    Herceptin®+Docetaxel

    Herceptin®+Docetaxel

    Biological: Herceptin® · Drug: docetaxel

Interventions

  • BiologicalHLX02

    8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.

  • BiologicalTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles

  • 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle

06

What researchers measure

Primary outcomes

  1. ORR 24

    calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1 by central imaging review (CIR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions,Complete Response (CR): Disappearance of all target lesions.Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm, Partial Response (PR): At least a 30% decrease in the sum ofdiameters of target lesions, taking as reference thebaseline sum diameters.Overall Response (OR) = CR + PR.

    Time frame: From time of First treatment to week 24

Secondary outcomes

  1. DoR

    The time from first documentation of CR or PR to the first documentation of progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1),At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or Unequivocal progression of existing non-target lesions (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: Up to 2 years

  2. DCR

    The percentage of patients who achieve CR, PR, or stable disease (SD) of at least 12 weeks

    Time frame: Up to 2 years

  3. CBR

    The proportion of patients who achieve CR, PR, or durable SD (SD ≥24 weeks)

    Time frame: Up to 2 years

  4. Median PFS up to 12 Months

    Median Progression Survival time assessed at 12 months.The probability of being alive without documented progression up to 12 months after randomization.

    Time frame: From time of first treatment to 12 months

  5. Overall Survival at 12, 24, and 36 Months

    the probability of being alive 12, 24, and 36 months after randomization

    Time frame: From time of first treatment to 36 months

07

Results

Posted May 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneHLX02+DocetaxelHerceptin®+Docetaxel
Started325327
Completed155137
Not completed170190

Outcome measures

PrimaryORR 24

calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1 by central imaging review (CIR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions,Complete Response (CR): Disappearance of all target lesions.Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm, Partial Response (PR): At least a 30% decrease in the sum ofdiameters of target lesions, taking as reference thebaseline sum diameters.Overall Response (OR) = CR + PR.

Time frame:
From time of First treatment to week 24
Reported as:
Number · percentage of responders
ORR 24
percentage of respondersHLX02+DocetaxelHerceptin®+Docetaxel
ORR 2471.170.9
SecondaryDoR

The time from first documentation of CR or PR to the first documentation of progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1),At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or Unequivocal progression of existing non-target lesions (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
Up to 2 years
Reported as:
Median · months
DoR
monthsHLX02+DocetaxelHerceptin®+Docetaxel
DoR10.61 (10.22 to 11.66)10.25 (8.97 to 11.53)
SecondaryDCR

The percentage of patients who achieve CR, PR, or stable disease (SD) of at least 12 weeks

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
DCR
percentage of participantsHLX02+DocetaxelHerceptin®+Docetaxel
DCR84.3 (80.4 to 88.3)87.2 (83.5 to 90.8)
SecondaryCBR

The proportion of patients who achieve CR, PR, or durable SD (SD ≥24 weeks)

Time frame:
Up to 2 years
Reported as:
Number · Clinical Benefit Rate(%)
CBR
Clinical Benefit Rate(%)HLX02+DocetaxelHerceptin®+Docetaxel
CBR80.9 (76.7 to 85.2)80.4 (76.1 to 84.7)
SecondaryMedian PFS up to 12 Months

Median Progression Survival time assessed at 12 months.The probability of being alive without documented progression up to 12 months after randomization.

Time frame:
From time of first treatment to 12 months
Reported as:
Median · months
Median PFS up to 12 Months
monthsHLX02+DocetaxelHerceptin®+Docetaxel
Median PFS up to 12 Months11.73 (11.53 to 12.06)10.55 (9.49 to 11.73)
SecondaryOverall Survival at 12, 24, and 36 Months

the probability of being alive 12, 24, and 36 months after randomization

Time frame:
From time of first treatment to 36 months
Reported as:
Number · percentage of participants with OS
Overall Survival at 12, 24, and 36 Months
percentage of participants with OSHLX02+DocetaxelHerceptin®+Docetaxel
12 months (%)88.988.4
24 months (%)71.467.6
36 months (%)57.554.0

Adverse events

Collected over Adverse events were assessed from the date the informed consent form is signed and no later than 30 (+2) days after the last dose, up to 14 months.All-Cause Mortality was assessed up to 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HLX02+Docetaxel128/325 (39.4%)78/325 (24%)320/325 (98.5%)
Herceptin®+Docetaxel142/327 (43.4%)81/327 (24.8%)321/327 (98.2%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventHLX02+DocetaxelHerceptin®+Docetaxel
Neutrophil count decreasedInvestigations33/32524/327
White blood cell count decreasedInvestigations16/32512/327
Febrile neutropeniaBlood and lymphatic system disorders12/32512/327
PneumoniaInfections and infestations8/32512/327
MyelosuppressionBlood and lymphatic system disorders5/3256/327
Pleural effusionRespiratory, thoracic and mediastinal disorders4/3255/327
Upper respiratory tract infectionInfections and infestations3/3251/327
DyspnoeaRespiratory, thoracic and mediastinal disorders1/3253/327
GastroenteritisInfections and infestations2/3250/327
DiarrhoeaGastrointestinal disorders2/3251/327
Most frequent other events
Showing 10 of 46
Most frequent other events
EventHLX02+DocetaxelHerceptin®+Docetaxel
White blood cell count decreasedInvestigations267/325276/327
Neutrophil count decreasedInvestigations266/325268/327
AnaemiaBlood and lymphatic system disorders166/325187/327
AlopeciaSkin and subcutaneous tissue disorders181/325174/327
Aspartate aminotransferase increasedInvestigations82/32574/327
DiarrhoeaGastrointestinal disorders76/32575/327
Alanine aminotransferase increasedInvestigations75/32569/327
Oedema peripheralGeneral disorders63/32554/327
Urinary tract infectionInfections and infestations53/32561/327
NauseaGastrointestinal disorders49/32558/327

Baseline characteristics

Age, Continuous
Age, Continuous(years)HLX02+DocetaxelHerceptin®+DocetaxelTotal
Median54 (30 to 80)53 (26 to 76)54 (26 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)HLX02+DocetaxelHerceptin®+DocetaxelTotal
Female325327652
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HLX02+DocetaxelHerceptin®+DocetaxelTotal
American Indian or Alaska Native000
Asian249252501
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7675151
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)HLX02+DocetaxelHerceptin®+DocetaxelTotal
China238237475
Philippines111526
Ukraine7675151
ECOG performance status
ECOG performance status(Participants)HLX02+DocetaxelHerceptin®+DocetaxelTotal
0(Fully active, able to carry on all pre-disease performance without restriction)138139277
1(Restricted in physically strenuous activity but ambulatory and able to carry out light work )186186372
Missing123
08

Study locations

88 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • First Affiliated Hospital of Guangzhou University of TMC
    Guangzhou, Guangdong, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • Sun Yat-sen University, Cancer Center
    Guanzhou, Guangdong, China
  • The University of Hong Kong-Shenzhen Hospital
    Shenzhen, Guangdong, China
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
  • Liuzhou General Hospital
    Liuzhou, Guangxi, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei, China
  • Hebei Cangzhou Central Hospital
    Cangzhou, Hebei, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei, China
  • The 2nd Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Nanjing Bayi Hospital
    Nanjing, Jiangsu, China
  • The Affiliated Drum Tower Hospital of Nanjing University
    Nanjing, Jiangsu, China
  • Nantong Tumor Hospital
    Nantong, Jiangsu, China
  • Wuxi 4th People's Hospital
    Wuxi, Jiangsu, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Hospital of Jilin University
    Chang chun, Jilin, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Jilin Province People's Hospital
    Changchun, Jilin, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • General Hospital of the Northern Theater of the Chinese People's Liberation Army
    Shenyang, Liaoning, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • Affiliated Hospital of Qinghai University
    Xining, Qinghai, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong, China
  • Jinan Central Hospital
    Jinan, Shangdong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shangdong, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai, China
  • Ruijin Hospital of Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Shannxi Provincial Tumor Hospital
    Xi'an, Shangxi, China
  • The 2nd Hospital of Xi'An Jiaotong University
    Xi'an, Shanxi, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Nanchong Central Hospital
    Nanchong, Sichuan, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjing, Tianjing, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    HanGzhou, Zhejiang, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • Beijing Cancer Hospital
    Beijing, China
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Chinese PLA General Hospital
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Metro Davao Medical and Research Center, Inc.
    Davao City, Davao 8000, Philippines
  • Cardinal Santos Medical Center
    San Juan, La Union 1502, Philippines
  • Manila Doctors Hospital
    Manila, Metro Manila 1000, Philippines
  • The Medical City
    Pasig City, Metro Manila 1605, Philippines
  • Cebu Doctors University Hospital
    Cebu City, 6000, Philippines
  • CI Kryvyi Rih Oncological Dispensary of DRC
    Kryvyi Rih, Dnepropetrovsk 50048, Ukraine
  • CNE"City Clin Hosp#4"of Dnipro City Council Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
    Dnipro, Dnipropetrovsk 49102, Ukraine
  • CI Carpathian Clinical Oncological Center
    Ivano-Frankivs'k, Ivano-Frankivsk 76018, Ukraine
  • CNE CCCH of Uzh CC Oncological Center, Ther Dept, SHEI UNU
    Uzhgorod, Outer Carpathian 88000, Ukraine
  • Transcarpathian Regional Clinical Oncological Dispensary
    Uzhgorod, Outer Carpathian 88014, Ukraine
  • Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council
    Lutsk, Warren 43018, Ukraine
  • CTPI Chernihiv Regional Oncological Dispensary
    Chernihiv, 14029, Ukraine
  • CI Chernivtsi RC Oncological Dispensary
    Chernivtsi, 58013, Ukraine
  • Communal Non-profit Enterprise Regional Center of Oncology
    Kharkiv, 61070, Ukraine
  • CI of Kherson Reg Council Kherson Regional Oncologic Dispensary
    Kherson, 73000, Ukraine
  • Khmelnytskyi Regional Oncological Dispensary
    Khmelnytskyi, 29000, Ukraine
  • Treatment-Diagnostic Center of Private Enterprise of PPC Atsynus
    Kropyvnytskyi, 25006, Ukraine
  • National Institute of Cancer
    Kyiv, 03022, Ukraine
  • CNE Kyiv City Clin Oncological Center of Ex Body of Kyiv CC(KCSA)
    Kyiv, 03115, Ukraine
  • Kyiv Сity Clinical Oncological Center
    Kyiv, 03115, Ukraine
  • CI of LRC Lviv Oncological Regional Treatment and Diagnostic Center
    Lviv, 79031, Ukraine
  • CI Odesa Regional Clinical Hospital
    Odesa, 65025, Ukraine
  • Odesa Regional Oncologic Dispensary
    Odesa, 65055, Ukraine
  • Poltava Reg Cl Onc Dispensary of PRC Chemotherapy Dept HSEI of Ukr UMSA
    Poltava, 36011, Ukraine
  • RCI Sumy Regional Clinical Oncological Dispensary Dept of of Chemotherapy Sumy SU
    Sumy, 40022, Ukraine
  • Podilskyi Regional Oncological Center
    Vinnytsia, 21029, Ukraine
  • CI Zaporizhzhia RC Onc Dispensary of ZRC Dept of Breast Pathology SI Zaporizhzhia MA of PGE of MoHU
    Zaporizhzhia, 69040, Ukraine
  • CI Zaporizhzhia Regional Clinical Oncological Dispensary of ZRC
    Zaporizhzhia, 69040, Ukraine
09

References and documents

Publications

  • Xu B, Zhang Q, Sun T, Li W, Teng Y, Hu X, Bondarenko I, Adamchuk H, Zhang L, Trukhin D, Wang S, Zheng H, Tong Z, Shparyk Y, Wang Q; HLX02-BC01 Investigators. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. BioDrugs. 2021 May;35(3):337-350. doi: 10.1007/s40259-021-00475-w. Epub 2021 Apr 7. PubMed 33826080 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2018, 24 months.

Results were first posted in May 2024, 5 years 5 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Mar 20, 2017
StartActual
Nov 2016
Primary completionActual
Nov 23, 2018
CompletionActual
Sep 28, 2021
Results first posted
May 17, 2024
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03084237
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Nov 2016
Primary completion
Nov 23, 2018
Completion
Sep 28, 2021
Results posted
May 17, 2024
Last update
May 17, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX02

Start the discussion